Abstract The complement protein C3d and C3d derived peptides that bind CD21 are known to enhance immunity to co-immunised antigens. In this study we have synthesised the minimal CD21 binding sequence of C3d ( 1227 LYN-VEA 1232 ) as mono, di and tri tandem repeats and derivatised the N-terminus with an acryloyl moiety. These acryloyl-(C3d) n peptides were co-polymerised with a acryloyl-T cell epitope (PAS1K) from the Porphyromonas gingivalis antigen the RgpA-Kgp proteinase-adhesin complex. The ability of C3d containing polymers to enhance T cell immunity in vitro and in vivo was evaluated. When used to stimulate in vitro PAS1K-primed or RgpA-Kgp complex-primed T cells the C3d containing PAS1K polymers induced a mixed and significantly (p \ 0.05) higher IL-4 and IFNc T cell response compared to that induced by the PAS1K peptide or polymer. PAS1K polymers containing tandem repeats of C3d induced a significantly (p \ 0.05) stronger maximal proliferative response, at the same antigenic dose, compared to that induced by the PAS1K peptide or polymer. When used as immunogens to prime T cells all of the C3d containing PAS1K polymers induced a dominant IFNc T cell response and reduced the antigen dose required for maximal proliferation 150-fold compared to that required for the PAS1K-peptide or polymer primed T cells. In conclusion, the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to an antigen and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in vitro stimulating antigen.
Introduction
Complement is typically regarded as a component of the innate immune system, however, degradation products particularly of the third complement factor, C3, are known to enhance the adaptive immune response to foreign antigens (Toapanta and Ross 2006) . Activation of C3 leads to the generation of C3dg and its degradation product C3d which form covalent bonds with foreign antigens, thus providing a ligand for complement receptor 2 (CD21). CD21 is expressed on B cells, follicular dendritic cells (FDCs), epithelial cells and subsets of T cells (Hourcade et al. 1989 ). CD21 engagement with C3d is known to lower the antigen activation threshold in B cells and induce proliferation as well as playing a role in B cell memory and tolerance and immunoglobulin class switching (Fearon 1998; Frade et al. 1992; Mongini et al. 1997; Toapanta and Ross 2006) . C3d-antigen complexes have been reported to enhance antigen processing and presentation by FDCs and they are retained on the cell surface for extended periods of time which has been shown to play a role in enhancing B cell activation, antibody production and memory (Bergmann-Leitner et al. 2006; Roozendaal and Carroll 2007; Zabel and Weis 2001) . Although, CD21 is expressed on 1-23 % of human and 4-5 % of mouse T cells the functional role played by CD21 on T cells is yet to be fully elucidated (Levy et al. 1992; Molnar et al. 2008) . However, CD21 expressing T cells have been shown to adhere strongly to C3d/CD21 bearing target cells and this enhanced binding is suggested to increase T cell activation and differentiation (Levy et al. 1992; Masilamani et al. 2002; Sinha et al. 1993) . In mice, antigen immunisation has been shown to result in the increase in lymph node CD21 ? T cells which is enhanced by the presence of C3d/CD21 bearing B cells (Kerekes et al. 1998; Molnar et al. 2008) .
C3d is a 35 kDa protein and although several binding sites for CD21 (CR2) have been postulated a 28 amino acid sequence ( 1209 KFLTTAKDKNRWEDPGKQLYNVEAT-SYA 1236 ) was found to contain the minimal binding domain 1227 LYNVEA 1232 (Lambris et al. 1985) . Dempsey et al. (1996) have shown that the fusion of C3d to a model antigen, hen egg lysozyme, enhanced the immune response to the antigen and that including two or three copies of C3d resulted in a 1,000 and 10,000-fold increase in the antibody response, respectively. Inclusion of multiple copies of C3d in either DNA, protein or polysaccharide based vaccines has been shown in several studies to enhance immunogenicity to the vaccine antigen, and a recent study suggests that six or more copies of C3d are necessary for efficient enhancement of the immune response (Green et al. 2003; Haas et al. 2004; Lou and Kohler 1998; Mitsuyoshi et al. 2005; Mkrtichyan et al. 2008; Suradhat et al. 2001; Toapanta and Ross 2006; Wang et al. 2006; Zhang et al. 2011) . Although, the 28 amino acid C3d binding region peptide is known to have reduced affinity for CD21, its incorporation into a vaccine construct does enhance the immune response to the vaccine antigen and multiple copies of the peptide, up to three have been shown to induce stronger immunity and CD21 affinity than one or two copies of the peptide (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990 ). Frade et al. (1992) have shown that a 16 residue synthetic peptide of C3d containing the minimal binding sequence 1227 LYNVEA 1232 does induce proliferation. In another study the multi-valency of a 13 residue C3d peptide (P13) containing the LYNVEA sequence was found to be essential for activation and proliferation as the multi-valent (four copies of P13) antigen was able to cross link CD21 bearing effector and target cells (Servis and Lambris 1989) . In this study we investigated whether the minimal C3d binding sequence LYNVEA when polymerised with a T cell epitope from the oral bacterium Porphyromonas gingivalis is sufficient to enhance antigen specific T cell proliferative and cytokine responses.
Materials and Methods

Chemicals and Reagents
Unless stated otherwise, chemicals used for peptide-resin assembly were of peptide synthesis grade or its equivalent.
(DIPEA), dimethylformamide (DMF), trifluoroacetic acid (TFA), piperidine, 9-flourenylmethloxycarbonyl (Fmoc)-protected amino acids, Fmoc-6-amino hexanoic acid (Ahx) and Fmoc-L-Ala-WANG resin were purchased from Auspep Pty. Ltd., Melbourne, Australia while Fmoc-PAL-PEG-PS resin was purchased from PerSeptive Biosystems, Inc., Framingham, MA. Dichloromethane (DCM), diethyl ether, phenol, trishydroxymethylaminomethane (Tris), ethylenediamine tetraacetic acid (EDTA), methanol (MeOH) and ammonium chloride were purchased from Ajax Finechem, NSW, Australia. Acrylamide was obtained from BioRad Laboratories, NSW, Australia. Acryloyl chloride, acetonitrile, sodium bicarbonate, sodium hydroxide (NaOH) and sodium chloride (NaCl) were obtained from MERCK, VIC, Australia. Triisopropylsilane (TIPS), guanidine-HCl, ammonium persulfate, tetramethylethylenediamine (TEMED), Dulbecco's phosphate buffered saline (PBS), complete Freund's adjuvant (CFA), incomplete Freund's adjuvant (IFA), Bovine Serum Albumin (BSA), L-glutamine, sodium pyruvate, gentamicin, penicillin, streptomycin, concanavalin A (ConA), N-lauroylsarcosine, and polyoxyethylene sorbitan monolaurate (Tween 20) were purchased from Sigma-Aldrich, NSW, Australia. Dulbecco's modified eagle's medium (DMEM) was obtained from SAFC Bioscience, VIC, Australia. Fetal bovine serum (FBS) was purchased from GIBCO Invitrogen Corporation, VIC, Australia. The antibodies (Abs) used in ELISPOT assay were bought from eBiosciences, San Diego, USA. 2-Mercaptoethanol and ammonium bicarbonate were obtained from ICN Biomedicals, Inc., Costa Mesa, USA. 2,4,6-Trinitrobenzene sulfonic acid (TNBSA) was kindly provided in powder form by Dr Denis Scanlon.
Synthesis and Purification of Acryloyl-Peptides
All peptides were synthesised as acryloyl-Ahx-(Lys) 4 derivatives and PAS1K (Acryloyl-Ahx-(Lys) 4 -NYTAHGS ETAWADPL, MW: 2,311.6 Da) and C3d-based peptides, C3d (Acryloyl-Ahx-(Lys) 4 -LYNVEA, MW: 1,387.7 Da), [C3d] 2 (Acryloyl-Ahx-(Lys) 4 -LYNVEALYNVEA, MW: 2,077.5 Da) and [C3d] 3 (Acryloyl-Ahx-(Lys) 4 -LYNVEA-LYNVEALYNVEA, MW: 2,767.2 Da) were synthesized using the Liberty TM Microwave Peptide Synthesizer (CEM Corporation, Matthews, NC, USA). Fmoc chemistry using Fmoc-protected amino acids and Fmoc-PAL-PEG-PS resin (0.20 mmol/g) or Fmoc-L-Ala-WANG (0.70 mmol/g) as the solid support was employed throughout the synthesis, with the completed peptides assembled as their C-terminal carboxyamide (PAS1K) or carboxyl forms (C3d-based peptides). Fmoc-Ahx-OH was manually coupled as a spacer (O'Brien-Simpson et al. 1997) to the N-terminus of each peptide via the addition of HBTU (5 equivalents), HOBT (five equivalents) and DIPEA (nine equivalents) in DMF. Fmoc-Ahx-OH coupling was monitored by the TNBSA test (Hancock and Battersby 1976) and following a negative TNBSA test, the resin was washed with DMF (1 9 10 ml) and DCM (5 9 10 ml).
Following removal of the Fmoc group 20 % piperidine/ DMF (v/v; 20 min) the peptide-resin was washed with DMF (6 9 5 ml), DCM (6 9 5 ml) and diethyl ether (6 9 5 ml), then dried under reduced pressure (18 h). Acryloylation of the dried Ahx-peptide-resins (0.1 mmol) were carried out manually using eightfold molar excess of acryloyl chloride (0.8 mmol) and 16-fold molar excess of DIPEA (1.6 mmol) in anhydrous DMF (4 ml) under nitrogen for 1 h and the reaction monitored using the TNBSA test.
The assembled acryloyl-Ahx-peptides were cleaved from the resin support and side chain deprotected using a mixture containing TFA/H 2 O/TIPS/phenol (92.5:2.5:2.5: 2.5; v/v/v/v; 5 ml) for 2 h. The TFA/peptide solution was collected by filtration and evaporated to approximately 1 ml under a stream of nitrogen at room temperature and the crude peptides precipitated in ice cold diethyl ether, centrifuged (4,0009g), washed with diethyl ether (3 9 40 ml) and dried under reduced pressure. The dried crude peptides were then dissolved in 0.1 % (v/v) TFA in milliQ water and purified using a semi-preparative ZORBAX 300 SB-C18 column (9.4 mm 9 25 cm) installed in a High Performance Liquid Chromatography (HPLC) 1100 system (Agilent Technologies Pty. Ltd., VIC, Australia) under a flow rate of 4 ml/min using buffer A (0.1 % v/v TFA in milliQ water) and buffer B (0.1 % TFA in 90 % acetonitrile, 10 % milliQ water, v/v) as the limiting solvent. Peptide detection was performed by absorbance at 214 nm. Fractions were collected and identified using electrospray mass spectrometry (Esquire LC-MS, Bruker Daltonics, NSW, Australia).
Polymerization of N-acryloyl-peptides N-acryloyl-Ahx-(Lys) 4 -PAS1K was polymerised singularly and with equimole equivalents of either N-acryloyl-Ahx-(Lys) 4 -C3d, N-acryloyl-Ahx-(Lys) 4 -[C3d] 2 or N-acryloylAhx-(Lys) 4 -[C3d] 3 in the presence of 50 mol equivalents of acrylamide as a co-monomer to produce the peptide polymers; poly-PAS1K, poly-PAS1K ? C3d, poly-PAS1K ? [C3d] 2 and poly-PAS1K ? [C3d] 3 , respectively. Monomers (acryloyl-peptides and acrylamide) were dissolved in de-gassed polymerisation buffer (6 M guanidine-HCl containing 2 mM EDTA and 0.5 M Tris buffer, pH 8) to yield a total monomer concentration of 2.5 % w/v. Polymerization was initiated at room temperature and under nitrogen by the addition of 4 % (w/w) ammonium persulfate of the molar concentration of monomers present and 5 lL of a 20 % v/v TEMED solution in polymerization buffer.
After 18 h the peptide polymers were dissolved in 50 mM ammonium bicarbonate and buffer exchanged using a Vivaspin 20 membrane column (GE Healthcare Life Sciences, NSW, Australia) at 8,0009g. The polymers were then purified via Gel Permeation Chromatography (GPC) using a Superdex 200 column (1.6 9 60 cm, GE Healthcare Life Sciences, NSW, Australia) installed in a 1100 HPLC system (Agilent Technologies Pty. Ltd., VIC, Australia) with a flow rate of 0.5 ml/min, using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer. Detection was performed by UV absorbance at 214 nm. Isolated peptide polymers ([95 % purity) were lyophilized using the Christ Freeze Dryer (Osterode am Harz, Germany) and stored at -20°C. 
Immunisation Protocols
T cell Proliferation Assays
Seven days after immunisation lymphocytes were prepared from pooled inguinal and popliteal lymph nodes of BALB/ c mice. Lymph nodes and spleens were collected in enriched Dulbecco's Modified Eagles Medium/Ham's Nutrient Mixture F12 (DMEM) supplemented with 10 % (v/v) heat inactivated (56°C, 30 min) foetal bovine serum (FBS), 2 mM glutamine, 2 mM sodium pyruvate, 0.1 mM 2-mercaptoethanol, 30 lg/ml gentamicin, 100 IU/ml penicillin and 100 lg/ml streptomycin (JRH Biosciences, Parkville, Australia), L-arginine (116 mg/ml), L-asparagine (36 mg/ml), and folic acid (6 mg/ml, Sigma, Melbourne, Australia) and single cell suspensions made by passing the lymph nodes or spleens through a wire mesh (200 lm).
Red blood cells were removed from the spleen cell suspension by treatment with ammonium tris chloride buffer (17 mM Tris-HCl, 140 mM ammonium chloride in MilliQ water, pH 7.2) for five minutes at room temperature, and then washed three times in enriched DMEM (500 g, 5 min at room temperature, IEC Centra GP8R refrigerated centrifuge, Thermo Electron Corporation, Melbourne, VIC, Australia.).
Monocytes and dead cells were removed from the lymph node cell suspension using Lympholyte Cells were then lysed with cell lysis buffer (30 mM TrisHCl, 100 mM EDTA, 1 % N-Lauroylsarcosine, pH 8) and harvested onto glass fibre filter mats using a Tomtec Harvester96 Ò MACH III cell harvester (Tomtec, Connecticut, USA). The glass fibre filter mats were then air dried, and sealed in plastic bags containing 5 ml of Betaplate Scint (Perkin Elmer, NSW, Australia) and incorporation of 3H-thymidine was measured using a Wallac Microbeta Trilux Liquid Scintillation Counter (Perkin Elmer, NSW, Australia). Data is expressed as stimulatory index (S.I.) ± SD where S.I. is calculated as the counts per minute (cpm) divided by the negative control cpm and statistically analysed using one-way ANOVA and Dunnett's 3T test (SPSS for Windows, Release 6.0; SPSS)..
ELISPOT Assay
ELISPOT assay was performed using the Millipore Multiscreen 96-well filtration plates (MAHAS450, Millipore, NSW, Australia). Plates were coated with anti-mouse cytokine capture antibodies (eBiosciences, San Diego, CA, USA), specific for IL-4 (catalogue number 14-7041, clone 11B11) and interferon-gamma (IFN-c, catalogue number 14-7312, clone R4-6A2), at a concentration of 4 lg/ml in 0.1 M sodium bicarbonate buffer (pH 9.5) and incubated overnight at 4°C.
The ELISPOT plates were then washed with Dulbecco's PBS and blocked with enriched DMEM for 1 h at 37°C. Lymph node T-cells and spleens were prepared as above. Antigen-primed lymph node cells (3 9 10 5 /well) were incubated with c-radiated (2,200 Rads) syngeneic spleen cells as a source of APCs (3 9 10 5 cells/well) and antigen: either RgpA-Kgp complex (5 lg/well) or acryloyl-Ahx-(Lys) 4 -PAS1K peptide or polymer antigens, poly-PAS1K, poly-PAS1K ? C3d, poly-PAS1K ? [C3d] 2 , poly-PAS1K ? [C3d] 3 (20 nmol/well). Plates were incubated at 37°C in an atmosphere of 5 % CO 2 in air for 48 h in a humidified incubator. The plates were then washed with phosphate buffered saline (PBS) containing 0.05 % v/v Tween 20 (PBST) three times and once with MilliQ water. Cytokinespecific biotinylated antibodies (eBiosciences, San Diego, CA, USA) specific for IL-4 (catalogue number 13-7042, clone BVD6-24G2) and IFN-c (catalogue number 13-7311, clone XMG 1.2) were added at a concentration of 2 lg/ml in Dulbecco's PBS/enriched DMEM (1:1, v/v) and incubated at room temperature for 2 h. Plates were washed six times with PBST and Streptavidin-Alkaline Phosphatase conjugate (Roche, Germany) was added to the plates at a 1:1,000 dilution in Dulbecco's PBS/enriched DMEM (1:1, v/v) and incubated for 1 h at room temperature. The plates were washed six times with PBST and three times with PBS, and 50 lL of substrate buffer (one tablet of 5-Bromo-4-chloro-3-indolyl phosphate/Nitro blue tetrazolium; BCIP/NBT, catalogue number B-565, Sigma-Aldrich, St Louis, MO, USA dissolved in 10 ml MilliQ water) was added per well. Spots were allowed to develop for 20-30 min, before stopping the reaction by washing with water. The spots were counted using EliSpot Reader Lite (version 2.9. Autoimmun Diagnostika GmbH Ebinger Strasse 4, Strassberg, Germany). Data is expressed as spot forming cells per million (SFC/million) and statistically analysed using one-way ANOVA and Dunnett's 3T test (SPSS for Windows, Release 6.0; SPSS).
Results and Discussion
Synthesis and Polymerisation of Peptide Polymers
To investigate the ability of the C3d minimal binding epitope LYNVEA (C3d) to act as a molecular adjuvant we initially synthesised via solid phase peptide chemistry using standard FMOC chemistry protocols the C3d peptide monomers as acryloyl-Ahx-derivatives. Based on the reports that multi-sequential copies of C3d enhance immunity, mono-di and tri-sequential LYNVEA repeats were produced. These acryloyl-Ahx-[C3d] n peptides although successfully synthesised were difficult to solubilise and the yield of purified peptides was less than 1 mg from a 0.1 mol scale synthesis. To address the solubility issue the peptides were synthesised with a four lysine spacer between the acryloyl-Ahx moiety and the N-terminus of the [C3d] n peptide. The four lysine [(Lys) 4 )] spacer has been used in a number of studies to improve the solubility of peptides but also has an added benefit in that it functions as a cathepsin B cleavage site thus enhancing antigen processing at a site removed from the peptide epitope when it is incorporated into a macro-molecule (Rejmanova et al. 1983; Sarobe et al. 1993) . With these features of the (Lys) 4 motif in mind we synthesised the [C3d] n and PAS1K peptides as acryloyl-Ahx-(Lys) 4 derivatives to enhance solubility and antigenicity, respectively. Furthermore, acryloyl-peptide monomers that are highly soluble in aqueous buffers were found to incorporate into polymers more readily O'Brien-Simpson et al. 1997) . Figure 1a shows the HPLC chromatogram of the crude acryloyl-Ahx-(Lys) 4 -PAS1K (Ac-PAS1K) with the highlighted peak being the desired peptide and the inserted analytical HPLC chromatogram of the purified Ac-PAS1K (observed mass = 2,312.7 Da, calculated mass = 2,311.6 Da). The secondary product eluting earlier at 14.8 min was found to be a lysine deletion (Fig. 1b-d) indicating an increasing hydrophobic nature of the minimal C3d binding sequence.
The free radical polymerisation approach using ammonium persulphate and TEMED to initiate and activate co-polymerisation of the acryloyl-Ahx-(Lys) 4 -peptides and acrylamide was used and the reaction conditions were based on earlier reports O'BrienSimpson et al. 1997 ). Similar to previous reports all of the peptide polymers eluted in the void volume of a size exclusion Superdex 200 column, which has an exclusion molecular weight of approximately 1.3 9 10 6 Da for globular structures (Fig. 2a) O'BrienSimpson et al. 1997) . Amino acid analysis of the purified ? ]. RP-HPLC was performed using a semipreparative Zorbax 300 SB-C18 column installed in a HPLC system. Peptide separation was achieved using 0-100 % buffer B (0.1 % TFA in 90 % acetonitrile, 10 % milliQ water, v/v) gradient over a period of 30 min at a flow rate of 4.0 ml/min b peptide polymers showed that the peptides contributed to 10-15 % w/w of the polymers and the ratio of PAS1K to C3d peptide was similar to the peptide monomer ratio at the initiation of polymerisation (i.e. 12.6 % for poly-PAS1K; 10.3 % for poly-PAS1K ? [C3d] ratio 1:1.1; 14.7 % for poly-PAS1K ? [C3d] 2 ratio 1:0.9 and 12.8 % for poly-PAS1K ? [C3d] 3 ratio 1:0.9). These incorporation rates of peptides into acrylamide polymers are similar to those found by others O'BrienSimpson et al. 1997) . Figure 2b shows a representative size exclusion profile of a PAS1K and [C3d] n co-polymer (poly-PAS1K ? [C3d] n ) eluting in the void volume (14.8 min) and the unreacted monomers eluting in the inclusion volume (38-46 min).
Although all of the acryloyl-Ahx-(Lys) 4 -peptides could be polymerised with a small molecular weight co-monomer such as acrylamide none of the peptides formed polymers or oligomers in the abscence of a small molecular weight co-monomer as determined by size exclusion chromatography using Superdex 200 and Superdex-peptide columns to detect peptide polymers or oligomers, respectively (data not shown). Different acryloyl/vinyl monomers are known to preferentially form block co-polymers (Sandler and Karo 1992) and steric hindrance is considered to be a major factor for monomers not forming single monomer species polymers. Each of the acryloyl-Ahx-(Lys) 4 -peptides eluted at high acetonitrile (buffer B) concentrations, indicating significant hydrophobicity (Fig. 1) . In the aqueous polymerisation buffer, this high level of hydrophobicity may result in increased steric hindrance about the acryloyl moiety, effectively suppressing free radical transfer in the polymerization reaction (Zou et al. 1993) . As a consequence, each of the peptide polymers-either containing a single peptide (PAS1K) or the heteropolymeric (PAS1K ? [C3d] n )-are likely to be block co-polymers.
T Cell Proliferative and Cytokine Responses Induced by the Peptide Polymers
A number of studies have shown that incorporation of C3d tandem repeats of either the whole protein sequence or peptides incorporating the CD21 binding site sequence into DNA-, recombinant protein-, or peptide-based immunogens enhances immunity to the co-immunised antigen (Bergmann-Leitner et al. 2007; Bower and Ross 2006; Lou and Kohler 1998; Servis and Lambris 1989; Tsokos et al. 1990; Zhang et al. 2011) . Furthermore, Servis and Lambris (1989) have shown that four copies of a 13 residue C3d peptide pendent from e-amino groups of lysine residues in a linear peptide template was sufficient to enhance T cell proliferation by cross-linking the CD21 receptor on the T cell and the antigen presenting cell. Free radical polymerisation of the minimal CD21 binding sequence LYNVEA from C3d and tandem repeats of it would incorporate into one immunogen both valency features known to enhance immunity. Using the PAS1K ? [C3d] n polymers we were able to investigate whether; the minimal CD21 binding sequence is sufficient to enhance immunity and if copy number or tandem repeats of LYNVEA induce a larger effect.
To investigate whether the peptide polymers would enhance antigen specific T cell responses, mice were immunised with either the PAS1K peptide or the native antigen the RgpA-Kgp complex and after 7 days the isolated lymph node T cells were stimulated in vitro with peptide and peptide polymers. Size exclusion chromatography was performed using a Superdex 200 column installed in a HPLC system. Separation was based on molecular size using an isocratic gradient of 50 mM ammonium bicarbonate as the running buffer at a flow rate of 0.5 ml/min. Detection was performed by absorbance at 214 nm doses via anergy and/or apoptosis (Falk et al. 2000; LaSalle and Hafler 1994) . Figure 3a (Fig. 3b) . Although poly-PAS1K did not induce a T cell response in the RgpA-Kgp complex primed T cells, poly-PAS1K ? [C3d] induce a T cell response at an antigen concentration of 20 nmol, albeit, significantly (p \ 0.05) weaker than that induced by the other stimulating antigens.
The lack of stimulation of T cells with poly-PAS1K and poly-PAS1K ? [C3d] may be due to antigen processing of the PAS1K peptide from the polymer back bone, resulting in the cleavage of the PAS1K peptide within the T cell epitope, thus reducing the amount of antigen available. Several studies have shown that conjugation of a T cell epitope into a construct reduces T cell stimulation as the epitope in the peptide construct requires enzymatic hydrolysis during antigen processing, which is not necessary for the free peptide. This reduces the amount of stimulatory peptide presented via MHC class II to T cells (Dyrberg and Oldstone 1986; Fitzmaurice et al. 2000; Lu et al. 1991; Partidos et al. 1992) .
The C3d tandem repeat peptide polymers poly-PAS1K ? [C3d] 2 and poly-PAS1K ? [C3d] 3 both induced a strong proliferative response. Several studies have shown that tandem repeats of C3d peptides enhances immunity to the co-immunised antigen by lowering the antigenic stimulation threshold (Bower and Ross 2006; Haas et al. 2004; Servis and Lambris 1989; Zhang et al. 2011) . Assuming Fig. 3 T-cell proliferative responses induced by peptide polymers. T-cells were isolated from the popilteal and inguinal lymph nodes of BALB/c 7 days after immunisation with antigen (peptide, peptidepolymer or the RgpA-Kgp complex) and then re-stimulated in vitro to determine T cell proliferative response. T-cells were isolated from PAS1K peptide (a) and RgpA-Kgp complex (b) immunised mice and were incubated with c-irradiated syngeneic spleen cells and either PAS1K peptide (dark diamond) or peptide polymer; poly-PAS1K (cross), poly-PAS1K ? C3d (square), poly-PAS1K ? [C3d] 2 (triangle) or poly-PAS1K ? [C3d] 3 (circle), concentration of the stimulating antigen was based on PAS1K. c, T-cells isolated from antigen (PAS1K peptide (dark diamond) or peptide polymer; poly-PAS1K (cross), poly-PAS1K ? C3d (square), poly-PAS1K ? [C3d] 2 (triangle) or poly-PAS1K ? [C3d] 3 (circle) immunised mice and were incubated with c-irradiated syngeneic spleen cells and the native antigen the RgpA-Kgp complex. T-cell proliferation was measured using that PAS1K is processed in a similar way for all of the peptide polymers, the inclusion of at least two tandem repeats of the minimal C3d sequence LYNVEA into the peptide polymers rather than a single copy was required to reduce the antigenic threshold so that the available peptide (PAS1K) was more efficient at stimulating a T cell proliferative response.
To investigate whether the C3d peptide polymers could enhance immunity in vivo, mice were immunised with each peptide polymer and the PAS1K peptide and the ability of the antigen primed T cells to proliferate was evaluated using the native antigen the RgpA-Kgp complex in vitro. Figure 3c shows that the PAS1K peptide and poly-PAS1K primed T cells had maximal proliferative responses at 3.13 and 1.56 lg/well of RgpA-Kgp complex, respectively and that the PAS1K peptide primed T cells had a significantly (p \ 0.01) stronger response compared to poly-PAS1K primed T cells. All of the PAS1K ? C3d peptide polymer primed T cells had maximal proliferative responses at a stimulating antigen concentration of 0.02 lg/well which was significantly (p \ 0.05) lower concentration than that of the maximal proliferative response by the PAS1K peptide or poly-PAS1K-primed T cells. Furthermore, the total T cell numbers isolated from the PAS1K ? C3d peptide polymer immunised mice was consistently 10 % higher in each experiment compared to T cell numbers isolated from PAS1K peptide and poly-PAS1K immunised mice.
The ability of C3d containing peptide polymers to enhance immunity to a far greater extent in vivo than in vitro may be due to the immunostimulatory effects of C3d on the antigen presenting cells. CD21 the receptor for C3d is known to be up regulated on APCs upon activation, thus enhancing cross-linking of APC's and T cells via CD21/C3d ligation and reducing the T cell activation threshold (Allison 1998 ). This would result in an increase of the polydiversity of the antigen specific T cell repertoire and their proportion within the whole T cell population. APC's in in vitro assays are treated chemically or with radiation to prevent them from proliferating and generating proteins. Thus, unlike in vivo-APC's, in vitro-APC's would not be able to up regulate CD21 on their surface, which may account for why the C3d containing peptide polymers were able to enhance a stronger immune response when used to immunise rather than stimulate.
To further investigate the effects of the C3d containing peptide polymers, T cells isolated from antigen primed mice were stimulated with antigen in vitro and the IFNc and IL-4 cytokines secreted were analysed by ELISPOT (Fig. 4) (Fig. 4a) . In RgpA-Kgp complex primed T cells the PAS1K peptide stimulated a mixed IL-4 and IFNc response (Fig. 4b) . Poly-PAS1K induced a significantly (p \ 0.05) weaker IL-4 and IFNc response compared to that induced by the other peptide polymers or PAS1K peptide. All of the PAS1K ? C3d containing polymers induced a mixed IL-4 and IFNc response which was significantly (p \ 0.05) stronger than the response induced by the PAS1K peptide with the RgpA-Kgp complex-primed T cells (Fig. 4b) . Figure 4c shows the IL-4 and IFNc response induced by the RgpA-Kgp complex on PAS1K peptide and peptide polymer primed T cells. The RgpA-Kgp complex induced a mixed IL-4 and IFNc response in PAS1K primed T cells, whereas poly-PAS1K primed T cells had a predominant IL-4 cytokine response. In contrast, all of the poly-PAS1K ? [C3d] n primed T cells had a predominantly and significantly (p \ 0.05) higher IFNc response compared to the response of PAS1K peptide or poly-PAS1K primed T cells, indicating that C3d may promote a Th1 cell phenotype.
C3d is known to promote and enhance both IL-4 and IFNc responses and is regarded as a general immunostimulatory agent (Bower and Ross 2006) . However, Wang et al. (2006) and Suradhat et al. (2001) reported that incorporation of multiple repeats of C3d molecules into DNA based vaccines resulted in a predominant Th2 phenotype. Alternatively, Allison (1998) and Knopf et al. (2008) demonstrated that immunising with tandem repeats of C3d sequences in recombinant protein and peptide based vaccines induced a Th1 cell phenotype. Furthermore, peptides containing the LYNVEA C3d sequence have been shown to directly interact with the T cell receptor inducing secretion of IFNc from T cells (Knopf et al. 2008) . When used as stimulating antigens in vitro, C3d containing peptide polymers tend to promote a mixed Th1/Th2 response indicating a general immunostimulatory role of C3d in the polymers. When used as immunising antigens, however, there is a strong promotion of a Th1 phenotype, which is consistent with the response when immunising with protein/peptide based vaccines containing C3d sequences (Allison 1998; Knopf et al. 2008) . The ability of poly-PAS1K and poly-PAS1K ? C3d to induce cytokine secretion in PAS1K primed and RgpA-Kgp complex primed T cells, while inducing weak or undectable proliferation, could be attributed to the incubation time and level of sensitivity of each assay. For certain antigens ELISPOT assays have been shown to be more sensitive compared to a 3 H-thymidine assay and at the point when 3 H-thymidine is added to detect proliferation, the response induced by weakly stimulating antigens is typically poorly detected (Macatangay et al. 2010; Schultes and Whiteside 2003; Troye-Blomberg et al. 1984) . Furthermore, T cell cytokine secretion can also be independent of proliferation (Jung et al. 1999) . These may in part explain the differences in the cytokine and proliferative responses induced when poly-PAS1K and poly-PAS1K ? C3d are used as stimulating antigens in vitro. According to the results presented here, however, peptide polymers used to immunise mice promoted strong T cell proliferative and cytokine secretion responses. When used to immunise mice poly-PAS1K induced a weaker proliferative response than peptide alone indicating that the PAS1K T cell epitope may not be as biologically available as PAS1K peptide. The reduced stimulation of T cells by the inclusion of PAS1K into a polymer was overcome by inclusion of monomeric or tandem repeats of the C3d sequence LYNVEA, which improved the magnitude of the T cell response and reduced the activation threshold compared to that induced by peptide polymer without C3d.
Concluding Remarks
In conclusion, we have demonstrated that acryloyl-peptides and acryloyl-derivatised immuno-stimulatory C3d peptide, can be co-polymerised to yield high molecular weight antigens. We have shown that valency of C3d in terms of tandem repeats but also copy number in a peptide polymer is important to enhance the immune response to the co-immunised antigen. Previous studies have included the minimal CD21 binding domain of C3d (LYNVEA) as part of a larger sequence, however, our data has shown that incorporation of just the minimal C3d binding residues is sufficient to enhance immunity and that the effect is more pronounced when C3d is part of the immunising antigen rather than an in vitro stimulating antigen. Our finding that the 6 residue sequence LYNVEA from C3d is sufficient to enhance immunity to a co-immunised antigen may further the adoption of C3d as an immunostimulatory component in vaccine formulations.
